PARTICULARS TO APPEAR ON THE OUTER PACKAGE CLEAR PLASTIC TRAY

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Versifel FeLV suspension for injection.

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

Each dose of 1 ml contains:

Active substance:

Inactivated feline leukaemia virus (FeLV) subtypes A, B and C (Kawakami-Theilen strain) including gp70 sub-unit antigen inducing anti-GP70 antibodies GMT ≥ 8.1 log₂

3. PACKAGE SIZE

10 x 1 dose 25 x 1 dose

4. TARGET SPECIES

Cats.

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Subcutaneous use.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}
Once broached use immediately.

9. SPECIAL STORAGE PRECAUTIONS

Store and transport refrigerated. Do not freeze. Protect from light.

10. THE WORDS "READ THE PACKAGE LEAFLET BEFORE USE"

Read the package leaflet before use.

11. THE WORDS "FOR ANIMAL TREATMENT ONLY"

For animal treatment only.

12. THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Zoetis UK Limited

14. MARKETING AUTHORISATION NUMBERS

Vm 42058/5122

15. BATCH NUMBER

Lot {number}

16. SPECIAL WARNING(S), IF NECESSARY

17. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Disposal: Read package leaflet.

18. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE

POM-V

Veterinary medicinal product subject to prescription

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS VIAL (1 ML SUSPENSION)

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Versifel FeLV

2. QUALITATIVE AND QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

FeLV

1 ml/dose

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

5. ROUTE(S) OF ADMINISTRATION

SC

6. THE WORDS "FOR ANIMAL TREATMENT ONLY"

For animal treatment only.

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Versifel FeLV suspension for injection for cats

2. COMPOSITION

Each dose of 1 ml contains:

Active substance:

Inactivated feline leukaemia virus (FeLV) subtypes A, B and C (Kawakami-Theilen strain) including gp70 sub-unit antigen inducing anti-GP70 antibodies GMT ≥ 8.1 log₂*

* As determined by mouse potency test (anti-gp70 antibodies, GMT denotes: geometric mean titre).

Adjuvants:

Quil A	20 μg.
Cholesterol	20 μg.
DDA (Dimethyl-diocatadecyl ammonium bromide)	10 μg.
Carbomer	0.5 mg.

Slightly opaque suspension.

3. TARGET SPECIES

Cats.

4. INDICATIONS FOR USE

For active immunisation of susceptible cats from 9 weeks of age to reduce the number of cats infected with FeLV and presenting clinical signs of the related disease.

No data are available in the studies to demonstrate protection against related clinical disease but prevention of infection is associated with protection against related clinical disease.

Onset of immunity: four weeks after the completion of the primary vaccination course. Duration of immunity: one year after the primary course and three years after the booster.

5. CONTRAINDICATIONS

None.

6. SPECIAL WARNINGS

Special warnings:

Vaccinate healthy animals only.

Do not vaccinate FeLV antigen positive cats. Therefore a test for presence of FeLV before vaccination is recommended.

No data are available for the efficacy of the product in presence of maternally derived antibodies.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental self-injection seek medical advice immediately and show the package leaflet or the label to the physician.

Pregnancy and lactation:

The use is not recommended during pregnancy and lactation.

Interaction with other medicinal products and other forms of interaction:

Safety and efficacy data are available which demonstrate that this vaccine can be either mixed with Zoetis' Versifel CVR and administered at a single site or administered on the same day as Zoetis' Versifel CVR, but at different sites.

No data are available on the duration of immunity of Versifel FeLV when administered together with Versifel CVR, this should be taken into account when considering re-vaccination intervals.

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medical product except the product mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

Overdose:

Following the administration of an overdose a larger proportion of animals might be expected to show a transient rise in rectal temperature (up to 40.5°C). Such transient rises are however expected to be of short duration (resolving within 48 hours). Frequency and duration of any temperature rise is usually lower following subsequent single dose administrations.

In the laboratory overdose study in which twice the recommended dose (2 ml) was administered, a larger proportion of animals developed a swelling at the injection site, (max. diameter up to 21 mm). The majority of these swellings resolved within a short period (within 2 weeks). A slightly larger proportion had swellings which remained detectable for 1 or 2 months however, by this time they were very small.

Major incompatibilities:

Safety and efficacy data are available which demonstrate that this vaccine can be mixed with, or administered at the same time as, Zoetis' Versifel CVR. Do not mix with any other veterinary medicinal product.

7. ADVERSE EVENTS

Cats:

Common (1 to 10 animals / 100 animals treated):

Injection site swelling¹

Elevated temperature^{2, 3}

Rare (1 to 10 animals / 10,000 animals treated):

Enlarged lymph node (localised)⁴

Very rare (<1 animal / 10,000 animals treated, including isolated reports):

Injection site pain

Diarrhoea, Vomiting

Allergic reaction, Anaphylactic shock (severe allergic reaction)⁵

Anorexia, Depression, Malaise⁶

¹Small (diameter usually smaller than 10 mm, maximal diameter 20 mm) very rarely associated with a brief period of discomfort and/or pain. The majority of these swellings resolve within a short period (2 weeks). A small proportion may remain detectable for 1 to 2 months however, by this time they are very small.

²Expected to be of short duration (resolving within 48 hours). Frequency and duration of any temperature rise is usually lower following subsequent administrations.

³When administered concurrently or simultaneously with Zoetis' Versifel CVR transient increases in temperature (up to 40.5 °C) are frequently observed following first vaccination lasting up to 5 days.

⁴Transient enlargement of the pre-scapular lymph node following the second dose administration, such enlargements are small in size (0.5 cm diameter) and only detected upon palpation of the area following injection.

⁵If such a reaction occurs appropriate treatment should be administered.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: {national system details}.

8. DOSAGE FOR EACH SPECIES, ROUTES AND METHOD OF ADMINISTRATION

Subcutaneous use

Primary vaccination:

Two 1 ml doses should be administered subcutaneously to cats from 9 weeks of age, with an interval of 3-4 weeks between doses.

Re-vaccination:

A single booster dose should be administered 1 year after the completion of the primary vaccination course. Thereafter a single booster dose should be administered to cats once every 3 years.

⁶Normally resolves within 24 hours.

9. ADVICE ON CORRECT ADMINISTRATION

Shake the vial well immediately before use.

For concurrent vaccination with Zoetis' Versifel CVR, a single dose of Versifel FeLV should be administered as described above. A single dose of Zoetis' Versifel CVR should then be administered at a separate site via the subcutaneous route.

For simultaneous vaccination with Zoetis' Versifel CVR, the contents of a single vial of Zoetis'Versifel CVR is reconstituted with the contents of a single vial of Versifel FeLV in place of the diluent. Once mixed, the contents of the vial should appear as a slightly coloured (pink/orange) opaque suspension; the mixed vaccines should be injected immediately via the subcutaneous route.

10. WITHDRAWAL PERIODS

Not applicable.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

Store and transport refrigerated (2 °C - 8 °C).

Do not freeze.

Protect from light.

Do not use this veterinary medicinal product after the expiry date which is stated on the label and tray after Exp. The expiry date refers to the last day of that month. Shelf life after first opening the immediate packaging: use immediately.

12. SPECIAL PRECAUTIONS FOR DISPOSAL

Medicines should not be disposed of via wastewater.

Ask your veterinary surgeon how to dispose of medicines no longer required.

These measures should help to protect the environment.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

13. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES

Vm 42058/5122

Pack sizes:

Clear plastic tray containing 10 x 1 ml dose.

Clear plastic tray containing 25 x 1 ml dose.

Not all pack sizes may be marketed.

15. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST REVISED

October 2023

Find more product information by searching for the 'Product Information Database' or 'PID' on www.gov.uk.

16. CONTACT DETAILS

Marketing authorisation holder and contact details to report suspected adverse reactions:

Zoetis UK Limited
1st Floor, Birchwood Building
Springfield Drive
Leatherhead
Surrey
KT22 7LP

Tel: +44 (0) 345 300 8034

Manufacturer responsible for batch release:

Zoetis Belgium Rue Laid Burniat 1 1348 Louvain-La-Neuve Belgium

17. OTHER INFORMATION

Vaccination stimulates active immunity against FeLV infection in healthy cats.

POM-V

Veterinary medicinal product subject to prescription

For animal treatment only.

Approved: 06 March 2024